Novavax (NVAX) Tops Q2 EPS by 12c, Revenues Miss

Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.30), $0.12 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $39.58 million.

“Novavax’ unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Since identifying a candidate vaccine to address the COVID-19 pandemic in March, we’ve secured significant funding, implemented global manufacturing capacity and completed and reported our successful Phase 1 trial. We’ve also expanded our senior leadership team to advance our efforts to bring NVX-CoV2373 to market as rapidly as possible and grow our infrastructure to support commercial stage operations.”

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Comfort Systems USA names new COO and Chief Strategy Officer
• People Inc. names new chief accounting officer as predecessor retires